Hillhurst Biopharmaceuticals Receives Study May Proceed Letter From US FDA to Initiate Phase 1 Clinical Trial of HBI-002

SAN DIEGO, CA (April 23, 2021) Hillhurst Biopharmaceuticals, Inc. ...